The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Open accessAbstract
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC. METHODS: In this double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, 559 patients with untreated metastatic, squamous NSCLC to receive 200 mg of pembrolizumab or saline placebo for up to 35 cycles; all the patients also received carboplatin and either paclitaxel or nanoparticle albumin-bound [nab]-paclitaxel for the first 4 cycles. Primary end points were overall survival and progression-free survival. RESULTS: After a median follow-up of 7.8 months, the median overall survival was 15.9 months (95% confidence interval [CI], 13.2 to not reached) in the pembrolizumab-combination group and 11.3 months (95% CI, 9.5 to 14.8) in the placebo-combination group (hazard ratio for death, 0.64; 95% CI, 0.49 to 0.85; P<0.001). The overall survival benefit was consistent regardless of the level of PD-L1 expression. The median progression-free survival was 6.4 months (95% CI, 6.2 to 8.3) in the pembrolizumab-combination group and 4.8 months (95% CI, 4.3 to 5.7) in the placebo-combination group (hazard ratio for disease progression or death, 0.56; 95% CI, 0.45 to 0.70; P<0.001). Adverse events of grade 3 or higher occurred in 69.8% of the patients in the pembrolizumab-combination group and in 68.2% of the patients in the placebo-combination group. Discontinuation of treatment because of adverse events was more frequent in the pembrolizumab-combination group than in the placebo-combination group (13.3% vs. 6.4%). CONCLUSIONS: In patients with previously untreated metastatic, squamous NSCLC, the addition of pembrolizumab to chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by Merck Sharp & Dohme; KEYNOTE-407 ClinicalTrials.gov number, NCT02775435 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“chemotherapy plus immune checkpoint blockade has been recently approved as the first-line regimen for NSCLC, including patients with KRAS mutations (45, 46).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Importantly, two remarkable phase III trials (KEYNOTE-189 and KEYNOTE-407) demonstrated that addition of pembrolizumab (Keytruda, anti-PD1) could significantly prolong the survival of NSCLC patients (45, 97).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“The promising results from these studies have led to the approval of pembrolizumab in combination with chemotherapy (carboplatin-pemetrexed) for metastatic, non-squamous NSCLC, and the approval of pembrolizumab in combination with chemotherapy (carboplatin and Taxol) for patients with squamous lung carcinoma, excluding those carrying EGFR or ALK mutations.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [45]
In the citing paper
“Toward this end, combinations of ICTs with concurrent and/or sequential chemotherapy are under extensive investigation, with phase III clinical data demonstrating overall survival and/or progression-free survival benefi t in NSCLC ( 63-66 ), small cell lung cancer ( 51,52 ), triple-negative breast cancer ( 67 ), bladder cancer ( 53 ), and head and neck squamous cell carcinoma ( 68 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [64]
In the citing paper
“Later, in two phase 3 clinical studies (KEYNOTE-189 and KEYNOTE-407), pembrolizumab combined with standard chemotherapy led to a better overall survival (OS) and PFS in NSCLC patients, relative to chemotherapy monotherapy [53, 54].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [54]
In the citing paper
“Moreover, ORR, median PFS, and median DOR reported for the two treatment arms were consistent with those reported in the KEYNOTE-189 and KEYNOTE-407 trials of pembrolizumab i.v.þ chemotherapy for the treatment of mNSCLC.22,23”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Self-citationNivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Self-citationFirst-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,006
Dudnik, E., Kareff, S. A., Moskovitz, M. T., Kim, C., Liu, S. V., Lobachov, A., Gottfried, T., Urban, D., Zer, A., Rotem, O., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001999 · Cited by 54
Takamori, S., Takada, K., Shimokawa, M., Matsubara, T., Fujishita, T., Ito, K., Toyozawa, R., Yamaguchi, M., Okamoto, T., Yoneshima, Y., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.026 · Cited by 55
Kehl, K. L., Zahrieh, D. M., Yang, P., Hillman, S. L., Tan, A. D., Sands, J. M., Oxnard, G. R., Gillaspie, E. A., Wigle, D. A., Malik, S. M., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.0039 · Cited by 55
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors
Liu, J., Cai, X., Lin, J., Zhang, Z., Zhou, Q., Zhang, X., Ma, L., Miao, Y., Zhang, R., Yu, C., et al. (2026) · Cell · doi:10.1016/j.cell.2025.12.002 · Cited by 59
Berghoff, A. S., Bellosillo, B., Caux, C., Langen, A. J. D., Mazières, J., Normanno, N., Preusser, M., Provencio, M., Rojo, F., Wolf, J., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000498 · Cited by 56
Self-citationGrivas, P. D., Monk, B. J., Petrylak, D. P., Reck, M., Foley, G., Guenther, S., Hennessy, D., Makris, C., & Moehler, M. H. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00665-1 · Cited by 56
Ross, A. E., Hurley, P. J., Tran, P. T., Rowe, S. P., Benzon, B., Neal, T. O., Chapman, C. G., Harb, R., Milman, Y., Trock, B. J., et al. (2019) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0176-8 · Cited by 56
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 57
Zhang, M., Fan, Y., Che, X., Hou, K., Zhang, C., Li, C., Wen, T., Wang, S., Cheng, Y., Liu, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00492 · Cited by 55
Self-citationSupplementation of l ‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
Satoh, Y., Kotani, H., Iida, Y., Taniura, T., Notsu, Y., & Harada, M. (2020) · Cancer Science · doi:10.1111/cas.14490 · Cited by 55
Riudavets, M., Mosquera, J., García‐Campelo, R., Serra-López, J., Anguera, G., Gallardo, P., Sullivan, I., Joaquín, A. B., del Carpio, L. P., Barnadas, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01677 · Cited by 55
Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
Cheng, Y., Zhang, L., Hu, J., Wang, D., Hu, C., Zhou, J., Wu, L., Cao, L., Liu, J., Zhang, H., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100225 · Cited by 56
Self-citationKim, C. G., Kim, G., Kim, K. H., Park, S., Shin, S., Yeo, D., Shim, H. S., Yoon, H. I., Park, S. Y., Ha, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002780 · Cited by 57
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
Benjamin, D. J., Xu, A., Lythgoe, M. P., & Prasad, V. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2265 · Cited by 54
Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges
Qubo, A. A., Numan, J., Snijder, J., Padilla, M. L., Austin, J. H. M., Capaccione, K. M., Pernia, M., Bustamante, J., O'Connor, T., & Salvatore, M. M. (2022) · Breathe · doi:10.1183/20734735.0147-2022 · Cited by 56
Borghaei, H., O'Byrne, K. J., Paz-Ares, L. G., Ciuleanu, T.-E., Yu, X., Płużański, A., Nagrial, A. M., Havel, L., Kowalyszyn, R. D., Audigier-Valette, C., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102065 · Cited by 57
Self-citationHuang, Z., Karaboué, A., Zeng, L., Lecoeuvre, A., Zhang, L., Li, X., Qin, H., Danino, G., Yang, F., Malin, M.-S., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105607 · Cited by 54
Self-citationNivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 56
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 53
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 54
Isono, T., Kagiyama, N., Takano, K., Hosoda, C., Nishida, T., Kawate, E., Kobayashi, Y., Ishiguro, T., Takaku, Y., Kurashima, K., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13736 · Cited by 54
Nesbitt, H., Logan, K. A., Thomas, K. G., Callan, B., Gao, J., McKaig, T., Taylor, M., Love, M., Stride, E., McHale, A. P., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.003 · Cited by 55
Checkpoint immunotherapy in pediatrics: here, gone, and back again
Long, A. H., Morgenstern, D. A., Leruste, A., Bourdeaut, F., & Davis, K. L. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349799 · Cited by 53
Ahmed, T., Lycan, T. W., Dothard, A. S., Ehrlichman, P. D., Ruiz, J., Farris, M. K., Topaloĝlu, Ü., Levine, B. J., Grant, S. C., Klepin, H. D., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.001 · Cited by 53
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Boesch, M., Baty, F., Rothschild, S. I., Tamm, M., Joerger, M., Früh, M., & Brutsche, M. H. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01365-2 · Cited by 53
Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 56
An update on treatment of penile cancer
Chadha, J. S., Chahoud, J., & Spiess, P. E. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221127254 · Cited by 53
Nanomedicine in Lung Cancer Immunotherapy
Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1144653 · Cited by 53
Stein, M. K., Pandey, M. K., Xiu, J., Tae, H., Swensen, J. J., Mittal, S., Brenner, A. J., Korn, W. M., Heimberger, A. B., & Martin, M. G. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00376 · Cited by 54
Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
Carbone, C., Piro, G., Noia, V. D., D’Argento, E., Vita, E., Ferrara, M. G., Pilotto, S., Milella, M., Cammarota, G., Gasbarrini, A., et al. (2019) · Mediators of Inflammation · doi:10.1155/2019/7652014 · Cited by 54
McLouth, L. E. S., Lycan, T. W., Levine, B. J., Gabbard, J., Ruiz, J., Farris, M. K., Grant, S. C., Pajewski, N. M., Weaver, K. E., & Petty, W. J. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.015 · Cited by 52
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
Sherman, S., Rotem, O., Shochat, T., Zer, A., Moore, A., & Dudnik, E. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.008 · Cited by 53
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 53
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer
Burgess, J. T., Rose, M., Boucher, D., Plowman, J., Molloy, C., Fisher, M. A., O’Leary, C. G., Richard, D. J., O'Byrne, K. J., & Bolderson, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01256 · Cited by 58
Dougan, M. L., Blidner, A. G., Choi, J. N., Cooksley, T., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Shannon, V. R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05707-3 · Cited by 53
Seban, R., Assié, J., Leprieur, E. G., Massiani, M.-A., Bonardel, G., CHOUAID, C., Deleval, N., Richard, C., Mezquita, L., Girard, N., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.024 · Cited by 53
Wang, M., Liang, H., Wang, W., Zhao, S., Cai, X., Zhao, Y., Li, C., Cheng, B., Xiong, S., Li, J., et al. (2020) · Cancer · doi:10.1002/cncr.33270 · Cited by 53
Iivanainen, S., Ekström, J., Virtanen, H., Kataja, V. V., & Koivunen, J. P. (2021) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-021-01564-0 · Cited by 55
Ramalingam, S. S., Novello, S., Guclu, S. Z., Bentsion, D., Zvirbule, Z., Szilasi, M., Bernabé, R., Syrigos, K., Byers, L. A., Clingan, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03318 · Cited by 52
Self-citationFurqan, M., Hejleh, T. A., Stephens, L. M., Hartwig, S. M., Mott, S. L., Pulliam, C. F., Petronek, M. S., Henrich, J. B., Fath, M. A., Houtman, J. C. D., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102318 · Cited by 55
Provencio, M., Granados, A. L. O., Coves-Sarto, J., Calvo, V., Fabregat, R. M., Dómine, M., Guirado, M., Carcereny, E., Fernández, N., Álvarez, R., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5959 · Cited by 52
Shiraishi, Y., Nomura, S., Sugawara, S., Horinouchi, H., Yoneshima, Y., Hayashi, H., Azuma, K., Hara, S., Niho, S., Morita, R., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00185-1 · Cited by 54
Self-citationFoster, C. C., Sher, D. J., Rusthoven, C. G., Verma, V., Spiotto, M. T., Weichselbaum, R. R., & Koshy, M. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1222-3 · Cited by 53
Liang, H., & Wang, M. (2019) · Cancer Management and Research · doi:10.2147/cmar.s212238 · Cited by 54
Kawachi, H., Tamiya, M., Tamiya, A., Ishii, S., Hirano, K., Matsumoto, H., Fukuda, Y., Yokoyama, T., Kominami, R., Fujimoto, D., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00882-5 · Cited by 52
Kobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 48
Han, B., Dong, L., Zhou, J., Yang, Y., Guo, J., Xuan, Q., Gao, K., Xu, Z., Lei, W., Wang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02898-4 · Cited by 56
Lonardi, S., Prete, A. A., Morano, F., Messina, M., Formica, V., Corsi, D. C., Orciuolo, C., Frassineti, G. L., Zampino, M. G., Casagrande, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002996 · Cited by 56
Yang, K., Li, J., Bai, C., Sun, Z., & Zhao, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01098 · Cited by 55
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Ayala‐Mar, S., Donoso‐Quezada, J., & González‐Valdez, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/8839978 · Cited by 52
Jiang, T., Chen, J., Xu, X., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., Yao, W., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01479-4 · Cited by 50
Self-citationDefining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52
Seto, T., Nosaki, K., Shimokawa, M., Toyozawa, R., Sugawara, S., Hayashi, H., Murakami, H., Kato, T., Niho, S., Saka, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004025 · Cited by 54
Self-citationTreatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Tamiya, M., Tamiya, A., Hosoya, K., Taniguchi, Y., Yokoyama, T., Fukuda, Y., Hirano, K., Matsumoto, H., Kominami, R., Suzuki, H., et al. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00843-y · Cited by 51
Seyedin, S. N., Hasibuzzaman, M. M., Pham, V., Petronek, M. S., Callaghan, C. M., Kalen, A. L., Mapuskar, K. A., Mott, S. L., Spitz, D. R., Allen, B. G., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.01.030 · Cited by 51
Zhou, H., Liu, J., Zhang, Y., Huang, Y., Shen, J., Yang, Y., Fang, W., & Zhang, L. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-0112-3 · Cited by 55
Aguilera, J. V., Paludo, J., McWilliams, R. R., Zhang, H., Li, Y., Kumar, A. B., Failing, J. J., Kottschade, L. A., Block, M. S., Markovic, S. N., et al. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000669 · Cited by 51
Choi, J. H., Medikonda, R. T., Saleh, L., Kim, T., Pant, A., Srivastava, S., Kim, Y., Jackson, C., Tong, L., Routkevitch, D., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1956142 · Cited by 53
Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51
Wang, J., Lu, S., Yu, X., Hu, Y., Zhao, J., Sun, M., Yu, Y., Hu, C., Yang, K., Song, Y., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103727 · Cited by 54
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Banna, G. L., Cantale, O., Bersanelli, M., Re, M. D., Friedlaender, A., Cortellini, A., & Addeo, A. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.490 · Cited by 50
The application of artificial intelligence and radiomics in lung cancer
Zhou, Y., Xu, X., Song, L., Wang, C., Guo, J., Zhang, Y., & Li, W. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa028 · Cited by 50
Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects
Wauthoz, N., Rosière, R., & Amighi, K. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1829590 · Cited by 53
Current Trends in Cancer Immunotherapy
Filin, I. Y., Solovyeva, V. V., Kitaeva, K. V., Rutland, C. S., & Rizvanov, A. A. (2020) · Biomedicines · doi:10.3390/biomedicines8120621 · Cited by 50
Schmalz, O., Jacob, C., Ammann, J., Liss, B., Iivanainen, S., Kammermann, M., Koivunen, J., Klein, A., & Popescu, R. A. (2020) · Journal of Medical Internet Research · doi:10.2196/18655 · Cited by 50
Morimoto, K., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950411 · Cited by 49
Mattes, M. D., Eubank, T. D., Almubarak, M., Wen, S., Marano, G., Jacobson, G. M., & Ma, P. C. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.012 · Cited by 48
Sadagopan, A., Michelakos, T. P., Boyiadzis, G., Ferrone, C. R., & Ferrone, S. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5970 · Cited by 49
Recent advances and remaining challenges in lung cancer therapy
Barr, T., Ma, S., Li, Z., & Yu, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002991 · Cited by 52
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Yousif, L. I., Screever, E. M., Versluis, D., Aboumsallem, J. P., Nierkens, S., Manintveld, O. C., de Boer, R. A., & Meijers, W. C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01414-4 · Cited by 51
Stares, M. D., Swan, A. M., Cumming, K., Ding, T.-E., Leach, J., Stratton, C., Thomson, F., Barrie, C., Maclennan, K., Campbell, S., et al. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.734735 · Cited by 47
Tjokrowidjaja, A., Lord, S. J., John, T., Lewis, C. R., Kok, P., Marschner, I. C., & Lee, C. K. (2022) · Cancer · doi:10.1002/cncr.34113 · Cited by 48
Chicas-Sett, R., Zafra, J., Rodríguez‐Abreu, D., Castilla-Martinez, J., Benítez, G., Salas-Salas, B., Hernández, S., Lloret, M., Onieva, J. L., Barragán, I., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.05.013 · Cited by 48
Fitzsimmons, T. S., Singh, N., Walker, T. D. J., Newton, C. L., Evans, D. G., Crosbie, E. J., & Ryan, N. A. J. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1192762 · Cited by 48
Low doses in immunotherapy: Are they effective?
Prabhash, K., Patil, V. M., Noronha, V., Joshi, A. D., Abhyankar, A. V., Menon, N. S., Banavali, S. D., & Gupta, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_29_19 · Cited by 48
Asahina, H., Oizumi, S., Takamura, K., Harada, T., Harada, M., Yokouchi, H., Kanazawa, K., Fujita, Y., Kojima, T., Sugaya, F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.020 · Cited by 47
Ninomiya, K., Oze, I., Kato, Y., Kubo, T., Ichihara, E., Rai, K., Ohashi, K., Kozuki, T., Tabata, M., Maeda, Y., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695062 · Cited by 48
Theelen, W. S. M. E., de Jong, M. C., & Baas, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.015 · Cited by 50
Wang, Z., Ying, J., Xu, J., Yuan, P., Duan, J., Bai, H., Guo, C., Li, L., Yang, Z., Wan, R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.13770 · Cited by 48
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 48
Li, N., Wang, J., & Zhan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752643 · Cited by 50
Fennell, D. A., Porter, C., Lester, J. F., Danson, S. J., Blackhall, F. H., Nicolson, M. C., Nixon, L. S., Gardner, G. M., White, A., Griffiths, G. O., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101595 · Cited by 47
Garassino, M. C., Gadgeel, S. M., Novello, S., Halmos, B., Felip, E., Speranza, G., Hui, R., Garon, E. B., Horinouchi, H., Sugawara, S., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100431 · Cited by 48
Self-citationMarin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Chen, Z., Yang, F., Jiang, Z., Sun, L., Wu, L., Han, Z., Fan, Y. L., Zhao, Y., Li, X., Xu, H., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01848-3 · Cited by 51
Self-citationYamaguchi, O., Imai, H., Minemura, H., Suzuki, K., Wasamoto, S., Umeda, Y., Osaki, T., Kasahara, N., Uchino, J., Sugiyama, T., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04055-7 · Cited by 47
Radiation and immunotherapy: emerging mechanisms of synergy
Breen, W. G., Leventakos, K., Dong, H., & Merrell, K. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-2019-cptn-07 · Cited by 47
Ksienski, D., Wai, E. S., Alex, D., Croteau, N. S., Freeman, A. T., Chan, A. M. Y., Patterson, T., Clarkson, M., Fiorino, L., Poonja, Z., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-541 · Cited by 46
Pan, L., Ma, Y., Li, Z., Hu, J., & Xu, Z. (2020) · Cell Biology International · doi:10.1002/cbin.11524 · Cited by 48
Bourhis, J., Stein, A., Paul de Boer, J., Van Den Eynde, M., Gold, K. A., Stintzing, S., Becker, J. C., Moran, M., Schroeder, A., Pennock, G., et al. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102172 · Cited by 47
The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, M., Frélaut, M., Baldini, C., Naigeon, M., Nencioni, A., Chaput, N., & Besse, B. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102394 · Cited by 48
Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48
Self-citationLiang, H., Lin, G., Wang, W., Huang, J., Yang, Y., Lan, Y., Wang, R., Cui, F., Hao, Z., Deng, H., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.02.14 · Cited by 45
Pecci, F., Cantini, L., Bittoni, A., Lenci, E., Lupi, A., Crocetti, S., Giglio, E., Giampieri, R., & Berardi, R. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00870-z · Cited by 48
Immunotherapy in NSCLC Patients with Brain Metastases
Buriolla, S., Pelizzari, G., Corvaja, C., Alberti, M., Targato, G., Bortolot, M., Torresan, S., Cortiula, F., Fasola, G., & Follador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137068 · Cited by 47
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 46
Signorelli, D., Giannatempo, P., Grazia, G., Aiello, M. M., Bertolini, F., Mirabile, A., Buti, S., Vasile, E., Scotti, V., Pisapia, P., et al. (2019) · BioMed Research International · doi:10.1155/2019/9056417 · Cited by 47
Combining Immunotherapy and Chemotherapy for Non–Small Cell Lung Cancer
Judd, J., & Borghaei, H. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.006 · Cited by 46
Metadata
- Authors
- Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid (L.P.-A.), and Hospital Universitario Virgen Macarena, Seville (D.V.) — both in Spain; Leningrad Regional Clinical Hospital, St. Petersburg, Russia (A.L.); Wollongong Oncology and Wollongong Private Hospital, Wollongong, NSW, Australia (A.T.); Istanbul Medeniyet University Hospital, Istanbul (M.G.), and Ankara University, Ankara (F.Ç.Ş.) — both in Turkey; Centre...
- Ankara University (TR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-22
- Volume
- 379
- Issue
- 21
- Pages
- 2040-2051
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2892640821
- Cited by
- 3,617
- References
- 26
- Citations by year
- 2026: 220 · 2025: 328 · 2024: 445 · 2023: 440 · 2022: 565 · 2021: 630 · 2020: 606 · 2019: 361 · 2018: 16
- FWCI
- 303.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Merck (N/A)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- pembrolizumab, lung squamous cell carcinoma, metastatic lung cancer, PD-L1 expression, immune checkpoint inhibitors, carboplatin, paclitaxel, nab-paclitaxel, first-line therapy, overall survival, progression-free survival, immune-related adverse events, treatment discontinuation, chemoimmunotherapy, PD-1 inhibitors
- MeSH terms
- Progression-Free Survival, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Carboplatin, Paclitaxel, Intention to Treat Analysis, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
